Friday November 18, 2022
Dr Bill Love speaks to Proactive Investors about how Destiny Pharma is addressing the Gl...
AMR is associated with the deaths of five million people worldwide each year. It has been estimated that, by 2050, the global death toll from AMR will rise to 10 […]
Tuesday November 15, 2022
XF-73 Dermal infection project advances into clinically enabling safety study with US Go...
Destiny Pharma plc (“Destiny Pharma” or “the Company”) XF-73 Dermal infection project advances into clinically enabling safety study as part of ongoing agreement with US Government’s NIAID Brighton, United Kingdom, […]
Monday November 14, 2022
New report highlights fast growing market for Live Biotherapeutics, Destiny Pharma’...
A new report highlights a fast growing market for Live Biotherapeutics, reaching $2.6bn by 2030. Destiny Pharma’s NTCD-M3 preventing C. difficile infections is leading play in this sector. View the […]
Wednesday October 19, 2022
Destiny Pharma R&D Investor Update meeting presentation recording
Destiny Pharma’s R&D Investor Update meeting, held on Tuesday 18 October 2022, is now available to watch via the link below:- R&D Investor Update meeting presentation
Thursday September 22, 2022
Notice of R&D Update Meeting
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Notice of R&D Update Meeting Brighton, United Kingdom – 22 September 2022 – Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on […]
Friday September 9, 2022
Exercise of Options and Total Voting Rights
Exercise of Options and Total Voting Rights Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, […]
Thursday September 8, 2022
Interim results for six months ended 30 June 2022
Destiny Pharma today announced its interim results for the 6 months ended 30 June 2022, which can be found here.
Thursday September 8, 2022
Interim results for six months ended 30 June 2022
Destiny Pharma today announced its interim results for the 6 months ended 30 June 2022, which can be found here.
Wednesday September 7, 2022
Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Inves...
Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Investment Conference Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development of novel medicines […]
Wednesday September 7, 2022